Male pattern hair loss (androgenetic alopecia) affects roughly 50 million men in the U.S. The treatment market spans FDA-approved drugs, natural supplements, topical treatments, and emerging therapies.

FDA-Approved Treatments

Only two drugs are FDA-approved for male pattern hair loss:

  • Finasteride (Propecia, 1mg/day): Oral 5-alpha reductase inhibitor that reduces DHT by ~70%. Prevents further loss in 86% of men and produces visible regrowth in 65%. Side effects (sexual dysfunction in ~2-4%) are the primary concern.
  • Minoxidil (Rogaine, 5% topical): Topical vasodilator. Moderate regrowth in 40-60% of users. Must be applied continuously — stopping reverses gains. Now available OTC.

Natural DHT Blockers

DHT blocker comparison, saw palmetto vs finasteride

For men who prefer non-pharmaceutical options or want to complement prescription treatment:

  • Saw Palmetto (320mg/day, liposterolic extract): The most studied natural 5-alpha reductase inhibitor. Multiple studies show modest hair count improvements, though effects are smaller than finasteride. Standardized extracts (85-95% fatty acids) are essential.
  • Pumpkin Seed Oil (400mg/day): A 2014 RCT showed 40% increase in hair count over 24 weeks — one of the stronger results for a natural compound.
  • Beta-Sitosterol: Plant sterol that may complement saw palmetto's mechanism. Evidence is primarily for prostate support, with hair benefits extrapolated from the shared DHT pathway.

Emerging Therapies

  • Low-Level Laser Therapy (LLLT): FDA-cleared devices. Growing evidence for stimulating follicle activity. Best as an adjunct, not standalone.
  • Platelet-Rich Plasma (PRP): Injections of concentrated growth factors. Promising but expensive, variable, and not standardized.
  • JAK Inhibitors: Remarkable results for alopecia areata. Not yet proven for androgenetic alopecia, but research is active.
  • Low-Dose Oral Minoxidil (2.5-5mg): Growing off-label use. More convenient than topical with potentially better systemic effects. Requires blood pressure monitoring.

The Market Shift

Pituitary gland and growth hormone secretion

The global hair loss treatment market is projected to reach $13 billion by 2028. Direct-to-consumer telehealth (Hims, Keeps, Roman) has dramatically increased prescription access — putting pressure on the supplement segment to differentiate on evidence and transparency. Natural DHT blockers occupy a specific niche: men who want to act proactively with non-pharmaceutical options, or those complementing prescription treatments with additional support. For the related science on growth hormone, see our HGH research coverage.